Laura Maiorino
Overview
Explore the profile of Laura Maiorino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2097
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
J Clin Invest
. 2025 Mar;
PMID: 40036068
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play a role as drivers of such responses. Despite advances in vaccine strategies, a...
2.
Buckley M, Arainga M, Maiorino L, Pires I, Kim B, Michaels K, et al.
Mol Ther
. 2025 Jan;
33(3):1105-1117.
PMID: 39797396
mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate...
3.
Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S, et al.
PNAS Nexus
. 2024 Dec;
3(12):pgae529.
PMID: 39677368
Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out...
4.
Madden P, Marina-Zarate E, Rodrigues K, Steichen J, Shil M, Ni K, et al.
bioRxiv
. 2024 Dec;
PMID: 39651117
Rare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We...
5.
Roerden M, Castro A, Cui Y, Harake N, Kim B, Dye J, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39521615
Background: Intratumoral heterogeneity (ITH) and subclonal antigen expression blunt antitumor immunity and are associated with poor responses to immune-checkpoint blockade immunotherapy (ICB) in patients with cancer. The underlying mechanisms however...
6.
Bhagchandani S, Yang L, Lam J, Maiorino L, Ben-Akiva E, Rodrigues K, et al.
Sci Immunol
. 2024 Sep;
9(99):eadl3755.
PMID: 39303017
Prolonging exposure to subunit vaccines during the primary immune response enhances humoral immunity. Escalating-dose immunization (EDI), administering vaccines every other day in an increasing pattern over 2 weeks, is particularly...
7.
Yousefpour P, Zhang Y, Maiorino L, Melo M, Arainga Ramirez M, Kumarapperuma S, et al.
bioRxiv
. 2024 Sep;
PMID: 39253464
Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out...
8.
Rodrigues K, Zhang Y, Aung A, Morgan D, Maiorino L, Yousefpour P, et al.
bioRxiv
. 2024 Sep;
PMID: 39229011
Vaccines incorporating slow delivery, multivalent antigen display, or immunomodulation through adjuvants have an important role to play in shaping the humoral immune response. Here we analyzed mechanisms of action of...
9.
Ramezani-Rad P, Marina-Zarate E, Maiorino L, Myers A, Michaels K, Pires I, et al.
bioRxiv
. 2024 Aug;
PMID: 39211109
The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies,...
10.
Sivanand S, Gultekin Y, Winter P, Vermeulen S, Tchourine K, Abbott K, et al.
Nat Metab
. 2024 Aug;
6(9):1668-1681.
PMID: 39160333
Metastases arise from subsets of cancer cells that disseminate from the primary tumour. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and...